Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma

doi:10.3748/wjg.v18.i42.6005

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 42

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9130)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-8) series, Tables (1-3) series.

Item

Count

PDF

809

HTML

7723

Figures (1-8)

426

Tables (1-3)

172

Sum=9130

Nov 14, 2012 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (38)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Nov 14, 2012; 18(42): 6005-6017
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6005

Full Size Figure Download Figure

Figure 6 Brivanib may be effective for the failure or resistance of first line anti-angiogenic therapy for vascular endothelial growth factor. In addition, there is a possibility that anti-FGF agents can be first line anti-angiogenic agents. FGF: Fibroblast growth factor; VEGF: Vascular endothelial growth factor; PDGF: Platelet-derived growth factor.

Citation: Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol 2012; 18(42): 6005-6017
URL: https://www.wjgnet.com/1007-9327/full/v18/i42/6005.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i42.6005